Testing a new medicine in healthy volunteers
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study tests an investigational drug called VX-581 in healthy volunteers to see how safe it is and how the body handles it. It is an early-phase trial, so it helps determine the right dose for future studies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old (typical for healthy volunteer trials, but not specified here)
- Your body mass index (BMI) is between 18.0 and 32.0 kg/m²
- You weigh more than 50 kg (about 110 pounds)
- You have not had a fever or other acute illness in the last 14 days
- You do not have any condition that could affect how your body absorbs drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new investigational medicine called VX-272 in healthy volunteers. Researchers want to check its safety and how it moves through the body, so you would not have the condition the medicine is being developed for.
This study tests how well a new tablet version of an experimental medicine (VX-581) is absorbed by the body. It may help researchers find the best way to give this medicine in the future.
This Phase 3 study looks at how well and how safely Vanzacaftor/Tezacaftor/Deutivacaftor works over the long term in people with cystic fibrosis who already took the study medicine before. It may help confirm the best long-term plan and spot important safety issues.
This trial tests how well cystic fibrosis (CF) medicine works for you using an “n-of-1” approach, meaning you try treatments in a structured, repeated way to see what helps you most. It may help your care team choose the best option for your specific CF genetics and health status.
This study looks at how well a highly effective cystic fibrosis (CF) medicine works in infants and young children, and what biological changes it causes. It may help families understand whether the medicine improves CF function and related measures early in life.
This study tests an experimental inhalable medicine called ARCT-032 for people with cystic fibrosis who cannot take or benefit enough from current CFTR modulators. The goal is to see if it safely improves lung function and quality of life.
Hear when a new Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.